Spotlight
All
Primers
Perspectives
Progress
Press
Skye Bioscience Photograph
Improving Obesity Health Outcomes via CB1 Inhibition
Skye Bioscience Chief Medical Officer, Puneet Arora, MD, MS, FACE, discusses how CB1 receptors help modulate energy storage and use rather than just suppressing appetite, and may be important to achieving healthier metabolism.
Skye Bioscience Photograph
GLP-1 Therapies: Breakthroughs vs Breakdowns
Skye Bioscience Chief Medical Officer, Puneet Arora, MD, discusses incretin drug hunger suppression, fat reduction and other benefits, and reviews complementary treatments to best address patients’ diverse needs.
Skye Bioscience Photograph
The Defended Biological State of Obesity
Skye Bioscience Chief Medical Officer, Puneet Arora, MD, MS, FACE, describes the body's fight to preserve energy stored as fat and the challenge to overcome this tendency with therapeutic drugs.
Skye Bioscience Photograph
The Detriment of Deranged Metabolism
Skye Chief Medical Officer, Puneet Arora, MD, MS, FACE, discusses how excess energy stored by the body's metabolic system as excess fat leads to obesity and other unhealthy conditions.
Skye Bioscience Photograph
The Metabolically Healthy Human
Skye Bioscience CMO describes the functioning of the human metabolic system in its "normal" healthy state, including managing energy and fat stores.
Skye Bioscience Photograph
The Bio Report Podcast: Obesity Therapy Unmet Needs
This podcast discusses unmet needs in the obesity space related to lack of tolerability, muscle loss, and weight rebound after therapy discontinuation, and the potential role of peripheral CB1 inhibition to help address these issues.
Skye Bioscience Photograph
Skye + Obesity Specialists Discuss Non-incretin Therapeutics
Led by Evercore equity analysts, Skye executives join notable obesity physicians to discuss the CB1 pathway, Skye's peripheral CB1 inhibitor, and the broader non-incretin toolkit supporting obesity care beyond the limits of GLP-1s.